Loading clinical trials...
Loading clinical trials...
Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed/Refractory Hematological Malignancies
Conditions
Interventions
Autologous CAR-T cells
Fludarabine
+1 more
Locations
1
China
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, China
Start Date
September 16, 2021
Primary Completion Date
June 1, 2024
Completion Date
June 1, 2026
Last Updated
September 6, 2022
NCT04570423
NCT07249528
NCT00131014
NCT06215118
NCT03050268
NCT06679101
Lead Sponsor
The Affiliated People's Hospital of Ningbo University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions